These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34653615)

  • 1. SARS COV-2- IgG antibodies in blood donors in pandemic - A game changer for policy makers.
    Mahapatra S
    Transfus Clin Biol; 2022 Feb; 29(1):11-15. PubMed ID: 34653615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study.
    Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR
    Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
    Benner SE; Patel EU; Laeyendecker O; Pekosz A; Littlefield K; Eby Y; Fernandez RE; Miller J; Kirby CS; Keruly M; Klock E; Baker OR; Schmidt HA; Shrestha R; Burgess I; Bonny TS; Clarke W; Caturegli P; Sullivan D; Shoham S; Quinn TC; Bloch EM; Casadevall A; Tobian AAR; Redd AD
    J Infect Dis; 2020 Nov; 222(12):1974-1984. PubMed ID: 32910175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India.
    Jain R; Mallya MV; Amoncar S; Palyekar S; Adsul HP; Kumar R; Chawla S
    Transfus Clin Biol; 2022 Feb; 29(1):60-64. PubMed ID: 34302953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial.
    Romera Martínez I; Avendaño-Solá C; Villegas Da Ros C; Bosch Llobet A; García Erce JA; González Fraile MI; Guerra Domínguez L; Vicuña Andrés I; Anguita Velasco J; González Rodríguez VP; Contreras E; Urcelay Uranga S; Pajares Herraiz ÁL; Jimenez-Marco T; Ojea Pérez AM; Arroyo Rodríguez JL; Pérez-Olmeda M; Ramos-Martínez A; Velasco-Iglesias A; Bueno Cabrera JL; Duarte RF
    Vox Sang; 2024 Jan; 119(1):27-33. PubMed ID: 37986640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors.
    Martin MC; Jimenez A; Ortega N; Parrado A; Page I; Gonzalez MI; Blanco-Peris L
    PLoS One; 2022; 17(2):e0264124. PubMed ID: 35202394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS-CoV-2 convalescent plasma donors.
    Hirani R; Hoad V; Gosbell IB; Irving DO
    Transfusion; 2022 Feb; 62(2):292-297. PubMed ID: 34936102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia.
    Nurarifah N; Brahmantyo HP; Wardhani SO; Hermanto DH; Arsana PM
    Front Immunol; 2021; 12():633323. PubMed ID: 34790190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.
    Li L; Tong X; Chen H; He R; Lv Q; Yang R; Zhao L; Wang J; Xu H; Liu C; Chen G; Chen S; Li C; Qiao J; Yang J; Wu Y; Liu Z
    Transfusion; 2020 Aug; 60(8):1765-1772. PubMed ID: 32627216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres.
    Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H
    Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.
    Zhang L; Pang R; Xue X; Bao J; Ye S; Dai Y; Zheng Y; Fu Q; Hu Z; Yi Y
    Aging (Albany NY); 2020 Apr; 12(8):6536-6542. PubMed ID: 32320384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population.
    Bloch EM; Patel EU; Marshall C; Littlefield K; Goel R; Grossman BJ; Winters JL; Shrestha R; Burgess I; Laeyendecker O; Shoham S; Sullivan D; Gehrie EA; Redd AD; Quinn TC; Casadevall A; Pekosz A; Tobian AAR
    Vox Sang; 2021 Aug; 116(7):766-773. PubMed ID: 33493365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.
    Li C; Yu D; Wu X; Liang H; Zhou Z; Xie Y; Li T; Wu J; Lu F; Feng L; Mao M; Lin L; Guo H; Yue S; Wang F; Peng Y; Hu Y; Wang Z; Yu J; Zhang Y; Lu J; Ning H; Yang H; Fu D; He Y; Zhou D; Du T; Duan K; Dong D; Deng K; Zou X; Zhang Y; Zhou R; Gao Y; Zhang X; Yang X
    Nat Commun; 2021 Jul; 12(1):4144. PubMed ID: 34230476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.
    Karbiener M; Farcet MR; Ilk R; Schreiner J; Lenart J; Powers N; Stewart JM; Tallman H; Kreil TR
    Transfusion; 2021 Apr; 61(4):1141-1147. PubMed ID: 33615484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection.
    Fazeli A; Sharifi S; Mohammadi S; Bahraini M; Arabkhazaeli A; Jelveh N; Eshghi P
    Transfus Apher Sci; 2022 Apr; 61(2):103302. PubMed ID: 34774440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Pre-Vaccination Donated Blood Is Free from Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) but Is Rich with Anti-SARS-CoV-2 Antibodies: A Cross-Section Saudi Study.
    Almaeen AH; Alduraywish AA; Ghazy AA; El-Metwally TH; Alayyaf M; Alrayes FH; Alinad AKM; Albulayhid SBH; Aldakhil AR; Taha AE
    Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates.
    Uzun G; Müller R; Althaus K; Becker M; Marsall P; Junker D; Nowak-Harnau S; Schneiderhan-Marra N; Klüter H; Schrezenmeier H; Bugert P; Bakchoul T
    Viruses; 2023 Jun; 15(6):. PubMed ID: 37376656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of IgG Antibodies to SARS-CoV-2 and Neutralizing Capabilities Using the Luminex
    King A; King G; Weiss C; Dunbar S; Das S
    Methods Mol Biol; 2022; 2511():257-271. PubMed ID: 35838966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.